Results 111 to 120 of about 8,311 (216)

Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia

eJHaem, 2023
Haya Jamali, David Wu, Lorinda Soma, Michael Linenberger, Mark H. Wener, Lev Silberstein   +5 more
doaj   +1 more source

Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025. [PDF]

Exp Hematol Oncol
Liang Y, Deng X, Wang Z, Xie C, Zheng L, Huang H, Yin S, Huang H.   +7 more
europepmc   +1 more source

Real-World Treatment Patterns for Waldenstrom Macroglobulinemia: Implications for Treatment Sequencing. [PDF]

J Korean Med Sci
Jang SY, Byun JM, Park SS, Kim Y, Park J, Shin DY, Koh Y, Kim I, Min CK, Yoon SS.   +9 more
europepmc   +1 more source

Walsh & Hoyt: Waldenstrom\u27s Macroglobulinemia

, 2005
This disorder is characterized by a proliferation of B-cells that are morphologically intermediate between plasma cells and lymphocytes and that secrete a monoclonal IgM.
John Kerrison, MD
core  

Treatment preferences in Waldenström macroglobulinemia: an international discrete choice experiment in 1455 patients. [PDF]

Blood Neoplasia
Becking AL, Nieuwkerk PT, Postek M, Amaador K, Bernelot Moens SJ, Bronsgeest L, D'Sa S, Faubert P, Harrington C, Kitchen P, MacDonald D, Minnema MC, McKinney A, Palomba ML, Tohidi-Esfahani I, Trotman J, Warden A, Kersten MJ, Vos JMI, WM-VOICE consortium.   +19 more
europepmc   +1 more source

Waldenström Macroglobulinemia Presenting With Hepatic Lesions: Case Report and Literature Review. [PDF]

Case Rep Hematol
Sternbach N, Bishara S, Gertz MA, Vaxman I.   +3 more
europepmc   +1 more source

Racial and socioeconomic disparities in patients with Waldenström Macroglobulinemia: a SEER database analysis. [PDF]

Sci Rep
Alvarez Soto A, Song J, Braun M, Kumar S.   +3 more
europepmc   +1 more source

POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia. [PDF]

Blood Adv
Zanwar S, Abeykoon J, D'Sa S, Roos-Weil D, Larson DR, Colby CL, Durot E, Kastritis E, Uppal E, Tomkins O, Morel P, Mondello P, Montes L, Paludo J, Ailawadhi S, Sarosiek S, Ogunbiyi O, Cornillet-Lefebvre P, Rajkumar SV, Quinquenel A, Dispenzieri A, Fonseca R, Gertz MA, Kumar S, Dimopoulos MA, Ansell SM, Treon S, Castillo JJ, Kapoor P.   +28 more
europepmc   +1 more source

MACROGLOBULINEMIA DE WALDENSTROM: ESTUDO DE CASO

Hematology, Transfusion and Cell Therapy, 2020
C.A.S. Souza, M.A.F. Chaves, V. Hoinatz, G. Zattera, L. Cichoski, J.T. Schiavini, L.F. Corbari, J. Plewka, M.F. Barros   +8 more
doaj   +1 more source

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up. [PDF]

Blood Adv
Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson BD, Walter HS, Greenwald D, Calvo R, Li Y, Rule S, Furman RR.   +18 more
europepmc   +1 more source